Cancer of Rectum
25
4
6
9
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.0%
3 terminated out of 25 trials
75.0%
-11.5% vs benchmark
4%
1 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (25)
Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer
Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients
Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Immunotherapy in Patients With Early dMMR Rectal Cancer
Tempus Priority Study: A Pan-tumor Observational Study
LIQUID BIOPSY FOCUSING ON CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA AS PRECISION MEDICINE IN GASTROINTESTINAL TUMORS
Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer
Abdominopelvic Cancer Prehabilitation
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
Colorectal Health Research Champions
Clinical Trial Comparing Standard Care Versus Prehabilitation in Patients Undergoing Cancer Surgery
Developing and Evaluating Product Messaging
Evaluation of cfDNA as a Marker of Response in Rectal Cancer
Educational Nursing Intervention Among Patients With Colorectal Cancer During Chemotherapy
Study to Nivolumab Following Preoperative Chemoradiotherapy
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Plan to Thrive: Extending Cancer Survivorship Care Beyond the Clinic
Survival of Patients With a Reduction in the Number of Lymph Nodes in Rectal Cancer After Neoadjuvant Chemoradiotherapy